Objective We evaluated whether percent time in target range (PTTR), risk of over-anticoagulation [international normalized ratio (INR) > 4], and risk of hemorrhage differ by race. As PTTR is a strong predictor of hemorrhage risk, we also determined the influence of PTTR on the risk of hemorrhage by race.
Introduction
Racial differences in outcomes related to cardiovascular disease, obesity, cancer, hypertension, asthma, and diabetes mellitus in minorities are well established. Although minorities shoulder a disproportionate burden of disease and are more likely to suffer poor outcomes, they remain under-represented in clinical trials [1, 2] . Under-representation is especially pronounced in cardiovascular trials. For example, African Americans comprise less than 2% of trial participants for the four non-vitamin-K antagonist oral anticoagulants (NoAC; dabigatran, rivaroxaban, apixaban, and edoxaban) approved since 2010 [3] [4] [5] [6] . Therefore, racial differences in drug response, if they exist, cannot be assessed from trial data [7] . For warfarin, the most widely used oral anticoagulant, investigators have led the charge to ensure that the evidence base for treatment is based on broad racial representation. Observational studies and clinical trials provide a robust case-study for illustrating race-related differences in anticoagulation response and factors that underpin this variable response [8] [9] [10] [11] [12] [13] .
Evidence from large cohorts supports the significant influence of clinical (e.g. age, amiodarone) and genetic (CYP2C9 and VKORC1 variants) factors on warfarin dose among European Americans and African Americans [8] [9] [10] [12] [13] [14] [15] [16] [17] . However, as we have shown recently [9] , the impact of and percent dose reduction associated with VKORC1 variants differ by race; European Americans require a larger dose decrease compared with African Americans. Moreover, CYP2C9*2 and CYP4F2 influenced the dose in European Americans, whereas rs12777823 influenced the dose only in African Americans [9] . The latter findings are supported by other reports [8, 10, 18] . This differential influence may explain why genotype-guided warfarin initiation predicted dose less accurately among African Americans compared with European Americans in the Clarification of Oral Anticoagulation through Genetics (COAG) trial and may explain divergent results wherein percent time in target range (PTTR) was increased by 3% among European Americans, but decreased by 8% among African Americans receiving genotype-guided dosing [11] .
Although racial differences in warfarin dose requirements and contributors of these differences have been evaluated, limited data exist on racial differences in PTTR, the risk of over-anticoagulation, and major hemorrhage. Here, we evaluate whether PTTR, the risk of over-anticoagulation [international normalized ratio (INR) > 4] , and the risk of hemorrhage differ by race and assess the influence of clinical and genetic factors on these outcomes. Moreover, as PTTR is a strong predictor of hemorrhage risk and often used as a surrogate outcome measure, we determine the influence of PTTR on the risk of hemorrhage by race.
Participants and methods
Participants older than 20 years of age initiating warfarin therapy were enrolled in an inception warfarin pharmacogenetics cohort study if the target INR range was 2-3 and therapy was managed at the anticoagulation clinic. Patients did not receive genotype-guided dosing. The study was carried out under the approval of the Institutional Review Boards of the University of Alabama at Birmingham and Emory University.
Patient demographics, indication for therapy, comorbidity, laboratory measurements, and medications were documented as reported previously [8, 9, 17, [19] [20] [21] [22] . During the monthly follow-up, dose, INR, and changes in concomitant medications that influence warfarin pharmacodynamics (antiplatelet agents) or pharmacokinetics (e.g. amiodarone) were documented. We assessed
, and *11 [rs28371685]), CYP24F2 (rs2108622), CYP2C singlenucleotide polymorphism (rs12777823) [10] , and VKORC1 (rs9923231) as described previously [21, 22] .
Outcomes definitions
Proportion of time spent in target range and quality of anticoagulation control Time (in days) to attain target INR and stable dose (defined as the average maintenance dose after the attainment of three consecutive INRs in the target range measured at least 2 weeks apart) was assessed in each patient. For each patient, PTTR was calculated as the percentage of interpolated INR values within the target range of 2.0-3.0 after attainment of first INR in the target range using the Rosendaal linear interpolation method [23] . We also present the proportion of time spent below and above the target range. As PTTR is a recognized risk factor of hemorrhage, we categorized patients' quality of anticoagulation control on the basis of cumulative PTTR in two ways. First, we considered PTTR of at least 60% (vs. <60%) as this has been evaluated as a predictor for hemorrhage among warfarin users in recent clinical trials and included in the recently proposed Hypertension, Abnormal renal/liver function, Stroke, Bleeding history, Labile INR (defined as PTTR < 60%), Elderly, Drug consumption/alcohol abuse (HAS-BLED) score [24] . Second, as the effectiveness of warfarin compared with the newer oral anticoagulants is related to the level of PTTR achieved, we also categorized PTTR as poor anticoagulation control (PTTR < 60%), good control (60 ≤ PTTR < 70%), and excellent control (PTTR ≥ 70%) [25] [26] [27] [28] [29] [30] .
Over-anticoagulation and major hemorrhage Over-anticoagulation was defined as INR more than 4. Major hemorrhages included serious, life-threatening, and fatal bleeding episodes [31] . As the focus of this study was to evaluate the association of race with the risk of major hemorrhages, minor hemorrhages (mild nosebleeds, microscopic hematuria, mild bruising, and mild hemorrhoidal bleeding) were excluded. During the 2-year follow-up, for all major hemorrhagic complications, the complication site (e.g. endoscopy of gastrointestinal tract), the severity of the event (e.g. requiring transfusion, surgical intervention, etc.), and laboratory findings (INR, hemoglobin/hematocrit, etc.) at the time of the event were documented objectively. Isolated subtherapeutic or supratherapeutic INRs in the absence of evidence of bleeding were not classified as events. The Center for Health Statistics was queried to verify the cause of death for all deceased to ensure inclusion of deaths because of hemorrhagic complications. All complications were reviewed independently by the Medical Director (T.M. B.) of the Anticoagulation Clinic. Only medically documented, adjudicated events were included in the analyses.
Statistical analysis
Analysis of variance was used to assess group differences for continuous variables and the χ 2 -test was used for categorical variables. The assumption of Hardy-Weinberg equilibrium was tested using the χ 2 -test and was satisfied for all singlenucleotide polymorphisms (P > 0.20). Multivariable logistic regression analysis was used to assess differences in PTTR (≥60 vs. <60) by race. The influence of race on the risk of over-anticoagulation (INR > 4) and hemorrhage was assessed using the counting process format in the proportional hazard model. In addition, the hemorrhage analysis accounted for PTTR categorized as poor anticoagulation control (PTTR < 60%), good control (60 ≤ PTTR < 70%), and excellent control (PTTR ≥ 70%). All analyses were carried out using SAS, version 9.3 (Statistical Analysis Software, Cary, North Carolina, USA) at a nondirectional α level of 0.05 accounting for demographic (e.g. age, race, sex, body surface area), clinical (comorbid conditions includingfor example -diabetes mellitus, chronic kidney disease (CKD; categorized on the basis of the estimated glomerular filtration rate ≥ 60, 30-59, and <30 ml/min/1.73 m 2 ), concurrent amiodarone use, and genetic (CYP2C9, CYP4F2, VKORC1, and rs12777823) factors.
Results
The baseline characteristics of the 1326 participants (mean age: 61.0 15.8 years) are presented in Table 1 . African Americans comprised 43.6% of the cohort. Compared with European Americans, African Americans were younger, more likely to be female, be a current smoker, and more likely to have venous thromboembolism, whereas atrial fibrillation was more common among European Americans. Hypertension, diabetes, and CKD were more prevalent among African Americans, whereas hyperlipidemia was more prevalent among European Americans. The use of concurrent antiplatelet agents, statins, and amiodarone was more frequent among European Americans, as was the prevalence of variants in CYP2C9 (*2, *3), VKORC1, and CYP4F2, whereas the prevalence of rs12777823 variants was higher among African Americans. CYP2C9 (*5, *6, *11) were only encountered in African Americans.
Percent time in target range and quality of anticoagulation control
Compared with European Americans, time to attain therapeutic INR (P = 0.03) and time to attain stable dose (P < 0.001) were longer in African Americans (Table 2) . Overall, patients spent 53.9% of the time in the target range, 28.6% of the time below the range, and 17.2% of the time above the range. European Americans spent 8.5% more time in the target INR range compared with African Americans (PTTR: 57.6 vs. 49.1%; P < 0.001; Table 2 ), whereas African Americans spent more time below the target INR range (proportion of time spent below: 32.9 vs. 25.2%; P < 0.001). Moreover, PTTR was more variable among African Americans compared with European Americans (SD: 22.7 vs. 19.9%; P = 0.002).
Overall, the quality of anticoagulation control was poor (PTTR < 60%) in 58.3% of the patients, good (60 ≤ PTTR < 70%) in 18.6% of the patients, and excellent (PTTR ≥ 70%) in 23.1% of the patients. More African Americans (68.7%) achieved poor anticoagulation control compared with European Americans (50.3%; P < 0.001), whereas more European Americans achieved good (22.9 vs. 13.1%; P < 0.001) and excellent (26.9 vs. 18.2%; P = 0.001, Table 2) anticoagulation control.
As PTTR of at least 60% (vs. <60%) is considered the benchmark for good anticoagulation control among warfarin users, we evaluated which predictors were associated with attainment of good or excellent anticoagulation control in race-combined and race-stratified analyses (Fig. 1) . In race-combined analyses, European Americans, men, patients prescribed warfarin for nonvenous thromboembolism, older patients (age ≥ 65), and patients without CKD were more likely to have good or excellent anticoagulation control (PTTR ≥ 60%). Concomitant therapy with amiodarone, statins, and anti-platelet agents, and possession of variants in genes known to influence warfarin response did not show a significant influence. Among European Americans, older patients (age ≥ 65) without CKD with a nonvenous 
Incidence (absolute risk) of hemorrhagic events
One-hundred and fifty-six hemorrhagic events occurred during 1912 person-years of follow-up (incidence rate: 8.1/100 person-years; 95% CI: 6.9-9.5). Hemorrhages included gastrointestinal (n = 94), genitourinary (n = 19), retroperitoneal (n = 7), intracranial (n = 13) bleeds, hemoptysis (n = 5), and hematomas ;(n = 18). ;Compared with European Americans (7.0 person-years; 95% CI: 5.6-8.8), African Americans (9.7/100 person-years; 95% CI: 7.7-12.1) had a higher incidence of hemorrhage (incidence rate ratio: 1.38, 95% CI: 1.01-1.89, P = 0.045). The incidence of hemorrhage was lower among patients attaining higher quality of anticoagulation control (Fig. 2b ) in race-combined and race-stratified analysis.
The incidence of hemorrhage did not differ by race among patients with poor (PTTR < 60%; P = 0.37), good (60 ≤ PTTR < 70%; P = 0.89), and excellent (PTTR ≥ 70, P = 0.11) anticoagulation control.
Relative risk of hemorrhagic events
Compared with European Americans, African Americans had a higher relative risk of hemorrhage (HR = 1.47, 95% CI: 1.08-2.01, P = 0.016). The risk of hemorrhage was lower among patients attaining higher quality of anticoagulation control (Fig. 2a) . Compared with patients who achieved poor anticoagulation control (PTTR < 60%), the risk of hemorrhage was 34% lower among those achieving good control (60 ≤ PTTR < 70%; P = 0.08) and 72% lower among those achieving excellent control (PTTR ≥ 70; P < 0.001).
After accounting for clinical and genetic factors, African Americans were at a 58% higher risk of major hemorrhage (HR = 1.58; 95% CI: 1.04-2.41; P = 0.03; Fig. 3 ) compared with European Americans. Female sex, body surface area, diabetes, amiodarone, statin, and possession of VKORC1, CYP4F2, and rs12777823 did not influence (P > 0.2) the risk of hemorrhage. Older age (P = 0.03), hypertension (P = 0.02), CKD (P = 0.003), and concurrent antiplatelet use (P = 0.004) were associated with an increased risk of hemorrhage. Possession of CYP2C9*3 (HR = 1.85; 95% CI: 1.07-3.2; P = 0.03) increased the risk of hemorrhage, whereas that of CYP2C9*2 (HR = 1.2; 95% CI: 0.78-1.85; P = 0.42) did not. The influence of CYP2C9*3 (P = 0.21) or CYP2C9*2 (P = 0.32) on hemorrhage risk did not differ by race. PTTR showed a significant association with major hemorrhage (P < 0.001).
Compared with PTTR less than 60%, those with 60 ≤ PTTR < 70% (HR = 0.62; 95% CI: 0.38-1.02; P = 0.058) and those with PTTR of at least 70% (HR = 0.27; 95% CI: 0.15-0.49; P < 0.001) had a lower risk of hemorrhage.
Discussion
To our knowledge, this is the first study to report PTTR and the risk of hemorrhage among African American and European American warfarin users managed through an anticoagulation service. We report two major findings. First, African Americans achieve a lower PTTR and are less likely to be classified as achieving good or excellent anticoagulation control (PTTR ≥ 60%) compared with European Americans. Second, African Americans have a higher risk of hemorrhage even after accounting for clinical and genetic risk factors and PTTR.
PTTR, an established measure of anticoagulation control, often serves as a surrogate for hemorrhage in studies assessing the efficacy of warfarin. Although numerous reports show the strong protective influence of higher PTTR on hemorrhage risk, most of these data are derived from patients of European descent, with limited representation of African Americans. For example, among participants in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) cohort, 59% of the INR values measured were between 2.0 and 3.0, with an overall mean TTR of 65 20%. European Americans comprised 90% of the cohort (n = 5000), with African Americans comprising only 5% [32] . Larger efforts (n = 48 830) have assessed differences in anticoagulation control by indication: atrial fibrillation versus venous thromboembolism. However, because of the limited representation (< 1%) of patients of African descent [33] , differences in anticoagulation control by race were not assessed. Similarly, in recent clinical trials that have led to the approval of four NoACs, patients of African descent comprised less than 2.0% of all participants [3] [4] [5] [6] . This is the first report assessing the VKORC1-PTTR association in African Americans. Previous studies reporting gene-anticoagulation associations have evaluated the gene-INR more than 4 relationship early in warfarin therapy. Although it seems intuitive that variants that influence dose would have similar associations (direction and effect) on PTTR, there are no studies reporting this. Moreover, it is likely that the impact of gene variants on warfarin response is dependent on time.
Ferder et al. [34] recently reported that the magnitude of the dose-predictive ability of VKORC1 and CYP2C9 decreased over time (43% at day 0, 12% at day 7, 4% at day 14, and 1% at day 21). This can be explained by the fact that dose changes over treatment time are not influenced by genotype alone but also the action (dose adjustments) guided by INR assessments. As opposed to the gene-INR relationship early in therapy, the gene-PTTR relationship captures response over followup duration accrued and is likely influenced by many factors (genetic, clinical, environmental) and interactions between these. We present both differences in PTTR by race and differences in PTTR categories by race; demonstrating that this difference persists after accounting for clinical and genetic factors. These findings are in agreement with the recent report on warfarin patients treated at the Veterans Health Administration [35] , showing racial differences in anticoagulation control despite management through an anticoagulation clinic.
African Americans have a higher risk of hemorrhage after accounting for clinical and genetic factors and PTTR. In agreement with previous reports, older age, hypertension, concurrent antiplatelet use, and possession of the CYP2C9*3 (but not CYP2C9*2) variant was associated with an increased risk of hemorrhage [36] . Improved anticoagulation control was associated with a significantly lower risk of hemorrhage [24, 25, 30, 37, 38] . Because higher PTTR is associated with a lower hemorrhage risk, it is convenient, and may even seem intuitive, to use PTTR as a continuous variable in evaluating its influence on hemorrhage. However, this approach may not conducive to a meaningful clinical interpretation. A significant body of evidence exists that supports that poor anticoagulation control (PTTR < 60%) is a predictor for hemorrhage among warfarin users [38] [39] [40] [41] . Moreover, this is widely recognized as the accepted quality metric for anticoagulation management services and is incorporated into risk prediction rules [24] . Improvement in PTTR, especially if the improvement results in a PTTR category, may be more meaningful. The fidelity of using PTTR categories is shown by recent analysis of NoAC clinical trial data [30, 37, 39] . Among Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) trial participants on warfarin, an increase in PTTR was associated with a decrease in the risk of hemorrhage. Moreover, compared with dabigatran (150 mg dose), the risk of hemorrhage was higher for warfarin users with PTTR less than 57%. Compared with dabigatran users, the risk of hemorrhage among warfarin users with PTTR 57-72% was similar and among those with PTTR more than 72%, the risk of hemorrhage was lower [30] . Similarly, compared with apixaban, the risk of hemorrhage was higher for warfarin users with PTTR less than 66% [37] .
Our results indicate the influence of anticoagulation control on hemorrhage by categorizing PTTR (poor: PTTR < 60%; good: 60 ≤ PTTR < 70%; and excellent: PTTR ≥ 70) among both African Americans and European Americans. Interventions that improve PTTR can be expected to produce a significant and similar reduction in the absolute and relative risk of hemorrhage in both race groups. PTTR of at least 70% was associated with the lowest risk of hemorrhage. Among European Americans with PTTR of at least 70%, the rate of major hemorrhage was similar to that reported in a large (n > 89 000) cohort of warfarin users from Sweden [40] . Our results suggest that the risk of hemorrhage can be further reduced by achieving excellent anticoagulation (PTTR ≥ 70%). However, even with a PTTR of at least 70%, African Americans have a higher risk of hemorrhage compared with European Americans.
Two trials that tested whether an intervention designed to improve dose prediction would result in higher PTTR yielded incongruent results [41, 42] . Evidence emerging after the trial initiation resulted in revision of the sample size estimates. The European Pharmacogenetics of Anticoagulant Therapy trial estimated that 400 patients would provide 80% power at α of 0.05 to detect a 7.0% difference in PTTR on the basis of an SD of 23%. The COAG trial estimated that 1022 patients would provide 80% power at α of 0.05 to detect a 5.5% difference in PTTR on the basis of a SD of 25%. These estimates were based on results from studies carried out in patients of mainly European descent [43] [44] [45] [46] . Our results indicate that variability (SD) around the mean PTTR is higher among African Americans. Therefore, interventions designed to improve PTTR should account for this variability.
The European Pharmacogenetics of Anticoagulant Therapy trial showed improved PTTR (54.6 vs. 45.7% at 4 weeks and 67.4 vs. 60.3% at 12 weeks; P < 0.001) among patients receiving personalized warfarin dosing (using clinical and genetic factors) versus standard dosing in 455 patients of largely European (99%) ancestry [47] . The COAG trial showed no overall improvement in PTTR (45.4 vs. 45.2%, P = 0.91 at 4 weeks) among patients receiving personalized warfarin dosing using clinical and genetic factors versus those receiving dosing on the basis of clinical factors alone. However, racestratified analysis showed improved PTTR among European Americans (48.9 vs. 46.1%, P = 0.15), but lower PTTR in African Americans (35.2 vs. 43.5%, P = 0.01) [11] . There was a significant interaction between dosing strategy and race (P = 0.003) in COAG. This could explain the observed differences in PTTR by race.
The heterogeneity introduced by race may explain the divergent findings across race groups in COAG. We have reported previously that the influence of known genetic variants on warfarin dose differs by race and that racestratified pharmacogenetic algorithms, rather than racecombined algorithms, should be used to guide warfarin dosing. Here, we show that African Americans achieve lower PTTR and fewer African Americans attain PTTRs of at least 60%. We also show that African Americans have a significantly higher risk of hemorrhage after accounting for PTTR. Most importantly, our results suggest that studies testing interventions designed to improve outcomes should be powered to show an increase in the proportion of patients attaining good or excellent anticoagulation control (PTTR ≥ 60%) and not solely on detecting a 5% improvement in PTTR.
Building on our previous work on racial differences in the impact of predictors on warfarin dose, we show that anticoagulation control and the risk of hemorrhage, the most feared complication among warfarin users, differ by race. Despite the introduction of NoACs, warfarin continues to be used widely, especially in African Americans [48] [49] [50] [51] . As warfarin continues to be used widely and improvement in anticoagulation control can reduce the risk of hemorrhage, personalized medicine interventions tailored to the African American warfarin users need to be developed.
